Welcome to our dedicated page for Quotient news (Ticker: QTNT), a resource for investors and traders seeking the latest updates and insights on Quotient stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quotient's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quotient's position in the market.
Quotient Limited (NASDAQ:QTNT) will announce its fiscal fourth quarter and full year financial results for the period ending March 31, 2021, before market open on June 1, 2021. A conference call will be held at 8:00 a.m. ET on the same day to discuss the results, with dial-in options provided for participants. Quotient, a leader in transfusion diagnostics, has developed the MosaiQ COVID-19 Antibody Microarray, which has received CE marking and FDA Emergency Use Authorization. The company is committed to improving diagnostic practices globally.
Quotient Limited (NASDAQ: QTNT) announced a private offering of $95 million in 4.75% Convertible Senior Notes due 2026, aimed at advancing its MosaiQ platform and supporting general corporate needs. The offering is to qualified institutional buyers, with possible additional notes totaling $15 million. Post-offering, Quotient expects approximately $166 million in cash. The notes feature a conversion option at $5.67, a 27.5% premium to the May 21 closing price, and may be redeemed from May 2024 under specific conditions.
Quotient Limited (NASDAQ:QTNT) announced positive results from a study of its MosaiQ Multiplex Molecular Disease Screening (MDS) Microarray, demonstrating sensitivity comparable to leading molecular diagnostic tests. The company is progressing its MDS product development and enhancing the Immunohematology (IH) microarray, with commercial launches planned for year-end 2021 in Europe. Quotient aims to deliver a platform capable of executing diverse diagnostic tests, showing potential for substantial improvements in laboratory workflows and operational efficiencies.
Quotient Limited (NASDAQ:QTNT) announced the appointment of Mr. Manuel Mendez as Chief Executive Officer, effective April 1, 2021. In connection with this, the Company will grant Mr. Mendez equity awards totaling approximately $6 million, including $3.33 million in restricted share units (RSUs) and $1.67 million in share options. The RSUs will vest over three years, with performance-based RSUs tied to financial targets. Quotient focuses on innovative diagnostic solutions, including its MosaiQ platform, designed to enhance laboratory efficiency and address COVID-19 testing needs.
Quotient Limited (NASDAQ:QTNT) will present at the Cowen 41st Annual Healthcare Conference on March 1, 2021, at 1:20 PM ET. The presentation will be available via live webcast on the company's investor relations page, with a replay archived for 90 days. Quotient specializes in transfusion diagnostics, aiming to transform diagnostics practices through its innovative MosaiQ technology, which offers fully automated, consolidated testing. Their MosaiQ COVID-19 Antibody Microarray has earned CE marking and FDA Emergency Use Authorization.
Quotient Limited (NASDAQ:QTNT) has appointed Manuel Mendez as CEO, effective April 1, 2021, succeeding Franz Walt, who is retiring after leading the company since 2018. Mendez brings over 30 years of experience in the diagnostics sector, previously serving as Senior VP and Chief Commercial Officer at Quest Diagnostics. He is tasked with guiding the company through the commercialization of the innovative MosaiQ platform for transfusion diagnostics. The Board praised Walt for his contributions, especially in preparing the MosaiQ system for commercial release, including obtaining CE marks and FDA Emergency Use Authorization for a COVID-19 test.
Quotient Limited (NASDAQ: QTNT), a diagnostics company based in Switzerland, announced its participation in the BTIG Virtual MedTech Conference on February 18, 2021. The company has over 30 years of experience in transfusion diagnostics and offers the MosaiQ platform, a fully automated testing solution designed to enhance laboratory efficiencies and clinical practices. Additionally, Quotient developed the MosaiQ COVID-19 Antibody Microarray, which has received FDA Emergency Use Authorization and CE marking, contributing to the global fight against COVID-19.
Quotient Limited (NASDAQ: QTNT) announced its third quarter fiscal 2021 results, reporting a 9.8% organic growth in Alba by Quotient reagents. The MosaiQ COVID-19 semi-quantitative antibody test received CE marking, with FDA EUA submission planned for February 2021. The company faces delays in its Expanded Immunohematology microarray CE mark submission due to pandemic-related disruptions, now expected in Q2 2021. Cash and equivalents stand at $143.5 million, supporting ongoing commercialization efforts. Product sales reached $8.8 million for Q3, with a gross margin of 43.2%.
Quotient Limited (NASDAQ:QTNT) will announce its fiscal third quarter financial results for the period ending December 31, 2020, on February 1, 2021, before market open. A conference call will follow at 8:00 a.m. ET on the same day, accessible via phone and webcast. The company is known for its MosaiQ system, a cutting-edge diagnostics platform that enhances laboratory efficiencies and practices. Notably, Quotient has developed a COVID-19 Antibody Microarray, which is CE marked and has received U.S. FDA Emergency Use Authorization.
